Tags : HBV


Gilead and Precision Biosciences Collaborates to Develop and Commercialize therapies

Shots: Gilead will be paying Precision $445M as a milestone payment at specific development stages in addition to the double digit royalties (<19%) from sales Under the agreement, Precision will manage development, formulation & preclinical evaluation of nucleases whereas, Gilead will do clinical development & commercialization of therapies The cccDNA (covalently closed circular DNA) allows […]Read More